http://crossborderbiotech.ca/2009/10/05/monday-biotech-deal-review-october-4-2009/ Biotechnology, Health and Business in Canada, the United States and Worldwide Mon, 23 Aug 2010 02:23:29 +0000 hourly 1 http://wordpress.com/ http://crossborderbiotech.ca/2009/10/05/monday-biotech-deal-review-october-4-2009/comment-page-1/#comment-1232 Monday Biotech Deal Review: January 4, 2010 « The Cross-Border Biotech Blog Mon, 04 Jan 2010 12:04:24 +0000 http://crossborderbiotech.ca/?p=3307#comment-1232 [...] has joined QLT Ophthalmics as Director responsible for the business unit.  [*Earlier in October, QLT sold QLT USA (which handled its palliative prostate cancer business) to its manufacturing partner [...] [...] has joined QLT Ophthalmics as Director responsible for the business unit.  [*Earlier in October, QLT sold QLT USA (which handled its palliative prostate cancer business) to its manufacturing partner [...]

]]> http://crossborderbiotech.ca/2009/10/05/monday-biotech-deal-review-october-4-2009/comment-page-1/#comment-1048 Monday Biotech Deal Review: October 25, 2009 « The Cross-Border Biotech Blog Mon, 26 Oct 2009 11:02:38 +0000 http://crossborderbiotech.ca/?p=3307#comment-1048 [...] Inc. (NASDAQ: QLTI) (TSX: QLT), which just sold its U.S. subsidiary to manufacturing partner TOLMAR, is re-arranging its Visudyne deal with Novartis.  QLT will [...] [...] Inc. (NASDAQ: QLTI) (TSX: QLT), which just sold its U.S. subsidiary to manufacturing partner TOLMAR, is re-arranging its Visudyne deal with Novartis.  QLT will [...]

]]>